On September 24, 2025, Hoth Therapeutics (NASDAQ: HOTH) announced the expansion of its intellectual property portfolio for HT-001, a topical therapeutic for chemotherapy-induced rash. CEO Robb Knie discusses the development and potential of HT-001, along with other updates, including the oncology drug HT-KIT, our obesity initiative in partnership with the U.S. Department of Veterans Affairs, and more. Learn more about the company: https://hoththerapeutics.com/ Watch the full YouTube interview here: https://youtu.be/99FydlxXwa8?si=uEm_KLqaggTfQSI8 And follow us to stay updated: https://www.youtube.com/@GlobalOneMedia?sub_confirmation=1
